Published in Neurotherapeutics on April 01, 2010
CGRP and migraine: could PACAP play a role too? Neuropeptides (2013) 0.90
PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells. Br J Pharmacol (2014) 0.82
Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine. J Mol Neurosci (2012) 0.81
Migraine in the era of precision medicine. Ann Transl Med (2016) 0.76
Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes (2016) 0.75
Cost of disorders of the brain in Europe. Eur J Neurol (2005) 6.41
Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci (2003) 4.69
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology (2007) 3.43
Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev (2000) 3.24
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev (2009) 3.22
Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun (1989) 3.03
Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA (1996) 2.83
Brain stem activation in spontaneous human migraine attacks. Nat Med (1995) 2.67
CGRP may play a causative role in migraine. Cephalalgia (2002) 2.40
International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev (1998) 2.30
PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain (2008) 2.17
Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet (1991) 2.11
Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol (2009) 1.97
Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia (1997) 1.78
Mast cell degranulation activates a pain pathway underlying migraine headache. Pain (2007) 1.74
2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache (2003) 1.71
VIP and PACAP: very important in pain? Trends Pharmacol Sci (1999) 1.68
VPAC and PAC receptors: From ligands to function. Pharmacol Ther (2008) 1.65
Neuropeptides activate human mast cell degranulation and chemokine production. Immunology (2007) 1.56
Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol (1996) 1.48
Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther (2007) 1.32
Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology (1991) 1.30
Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep (2009) 1.28
Three bulbospinal pathways from the rostral medulla of the cat: an autoradiographic study of pain modulating systems. J Comp Neurol (1978) 1.24
The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev (2005) 1.23
Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab (1993) 1.20
Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res (1999) 1.19
Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol (2002) 1.13
A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol (1994) 1.10
New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann N Y Acad Sci (2006) 1.09
Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol (2007) 1.09
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia (2008) 1.09
Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther (1993) 1.04
Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci (2004) 1.03
Origin and Co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech (2001) 1.00
Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept (1995) 0.99
Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst (1999) 0.99
Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol (1993) 0.94
Increased plasma histamine levels in migraine patients. Clin Allergy (1982) 0.93
Arterial responses during migraine headache. Lancet (1990) 0.92
Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport (1995) 0.91
A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology (2006) 0.91
Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res (1999) 0.89
Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept (1997) 0.88
The headache-inducing effect of cilostazol in human volunteers. Cephalalgia (2006) 0.87
Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia (2002) 0.87
The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia (2009) 0.87
Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain (2002) 0.86
Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia (2006) 0.86
Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia (2001) 0.85
Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport (2001) 0.84
Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain (2008) 0.83
Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP) in the rat median eminence and pituitary. J Neuroendocrinol (1995) 0.83
The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol (1995) 0.83
Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport (2002) 0.82
PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab (1993) 0.82
Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res (1998) 0.82
The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept (2007) 0.82
Pituitary adenylate cyclase activating polypeptide is expressed in autonomic neurons. Regul Pept (1995) 0.78
Finding new drug targets for the treatment of migraine attacks. Cephalalgia (2009) 0.78
Anatomical basis for a parasympathetic and sensory innervation of the intracranial segment of the internal carotid artery in man. Possible implication for vascular headache. J Neurol Sci (1991) 0.76
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Cost of disorders of the brain in Europe. Eur J Neurol (2005) 6.41
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 4.63
Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol (2013) 3.87
Evidence for a vascular factor in migraine. Ann Neurol (2011) 2.93
Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia (2013) 2.87
Provocation of migraine with aura using natural trigger factors. Neurology (2013) 2.39
Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet (2010) 2.35
Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology (2006) 2.28
PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain (2008) 2.17
Vestibular migraine: diagnostic criteria. J Vestib Res (2012) 2.04
Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. Neurology (2003) 1.99
Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol (2009) 1.97
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia (2010) 1.88
Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia (2010) 1.65
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain (2014) 1.52
Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol (2009) 1.51
A systematic comparison of motion artifact correction techniques for functional near-infrared spectroscopy. Front Neurosci (2012) 1.46
Consensus document on European brain research. Eur J Neurosci (2011) 1.45
On the methodology of drug trials in migraine with aura. Cephalalgia (2010) 1.45
[Clinical symptoms and pathophysiology of migraine]. Ugeskr Laeger (2008) 1.40
BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther (2005) 1.34
Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain (2003) 1.25
No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol (2005) 1.25
Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology (2013) 1.21
ICHD-3 beta is published. Use it immediately. Cephalalgia (2013) 1.20
Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. J Headache Pain (2011) 1.14
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther (2009) 1.13
Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology (2006) 1.08
Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache (2014) 1.06
Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. Headache (2002) 1.03
Characterization of consistent triggers of migraine with aura. Cephalalgia (2010) 1.01
Experimental muscle pain and tenderness following infusion of endogenous substances in humans. Eur J Pain (2003) 0.99
Chronic migraine--classification, characteristics and treatment. Nat Rev Neurol (2012) 0.99
A new technology for detecting cerebral blood flow: a comparative study of ultrasound tagged NIRS and 133Xe-SPECT. Neurocrit Care (2012) 0.95
Predictors of outcome of the treatment programme in a multidisciplinary headache centre. Cephalalgia (2010) 0.94
Emerging migraine treatments and drug targets. Trends Pharmacol Sci (2011) 0.94
The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab (2002) 0.93
Differential expression of BK channel isoforms and beta-subunits in rat neuro-vascular tissues. Biochim Biophys Acta (2008) 0.93
Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia (2013) 0.93
New plans for headache classification: ICHD-3. Cephalalgia (2010) 0.92
Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol (2004) 0.92
Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol (2007) 0.92
Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache (2011) 0.92
Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. Neurosci Lett (2010) 0.90
Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia (2012) 0.89
Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia (2011) 0.89
Migraine and structural abnormalities in the brain. Curr Opin Neurol (2014) 0.89
Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation. Cephalalgia (2013) 0.89
Pathophysiology of tension-type headache. Curr Pain Headache Rep (2005) 0.88
Low frequency oscillations in cephalic vessels assessed by near infrared spectroscopy. Eur J Clin Invest (2012) 0.87
Possible site of action of CGRP antagonists in migraine. Cephalalgia (2011) 0.87
Interhemispheric differences of fMRI responses to visual stimuli in patients with side-fixed migraine aura. Hum Brain Mapp (2013) 0.86
Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia (2012) 0.86
[Medication overuse headache]. Ugeskr Laeger (2006) 0.86
A naturalistic glyceryl trinitrate infusion migraine model in the rat. Cephalalgia (2011) 0.86
Implications of clinical subtypes of migraine with aura. Headache (2006) 0.86
Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology (2008) 0.86
The in vivo effect of adrenomedullin on rat dural and pial arteries. Eur J Pharmacol (2006) 0.85
Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalalgia (2013) 0.85
Current and potential future drug therapies for tension-type headache. Curr Pain Headache Rep (2003) 0.85
Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache (2010) 0.85
Migraine before rupture of intracranial aneurysms. J Headache Pain (2013) 0.85
Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol (2010) 0.85
Sources of variability of resting cerebral blood flow in healthy subjects: a study using ¹³³Xe SPECT measurements. J Cereb Blood Flow Metab (2013) 0.84
Spontaneous low-frequency oscillations in cerebral vessels: applications in carotid artery disease and ischemic stroke. J Stroke Cerebrovasc Dis (2010) 0.84
Genome-wide association study identifies four loci associated with eruption of permanent teeth. PLoS Genet (2011) 0.84
Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. Cephalalgia (2013) 0.84
The future of headache classification and classification research. Cephalalgia (2009) 0.83
Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase. Headache (2011) 0.83
The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab (2004) 0.83
Prostaglandins in migraine: update. Curr Opin Neurol (2013) 0.83
The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept (2007) 0.82
Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes. Headache (2014) 0.82
Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study. BMJ Open (2012) 0.82
Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain (2008) 0.82
Future possibilities in migraine genetics. J Headache Pain (2012) 0.82
Licence for Botox in so-called chronic migraine. Lancet (2010) 0.81
Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs (2012) 0.81
Migraine and risk of hemorrhagic stroke: a study based on data from general practice. J Headache Pain (2014) 0.81
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain (2012) 0.81
Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia (2011) 0.81
Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. J Headache Pain (2010) 0.81